Pacific Shores Medical Group

Summary

Pacific Shores Medical Group is a medical facility located in Long Beach, California. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Pacific Shores Medical Group is involved with conducting 82 clinical trials across 97 conditions. There are 3 research doctors associated with this hospital, such as Danny Nguyen, MD, Nishan Tchekmedyian, M.D., and Mohammad Barakat.

Top PIs

Clinical Trials running at Pacific Shores Medical Group

Lung Cancer

Cancer

Solid Tumors

Liver Failure

Pancreatic Cancer

Neuroendocrine Carcinoma

Pulmonary Disease

Acute Viral Respiratory Infection

Bronchial Tumors

Gastrointestinal Cancer

Repotrectinib

for Solid Tumors

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Recruiting

1 award

Phase 1 & 2

7 criteria

U3-1402

for Non-Small Cell Lung Cancer

This trial is testing HER3-DXd, a new drug for advanced lung cancer patients who haven't responded to other treatments. The drug targets a protein on cancer cells and delivers a toxic substance to destroy them.

Recruiting

1 award

Phase 1

18 criteria